Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlucoWatch BlueCross BlueShield TEC Assessment Could Spur Adoption

This article was originally published in The Gray Sheet

Executive Summary

CygnusGlucoWatch Biographer use in conjunction with standard blood glucose monitoring could result in fewer complications from severe diabetes, such as retinopathy and blindness, according to a recent study by the company

You may also be interested in...



Cygnus GlucoWatch Distributor Asks For Proof Of Fiscal Stability By Oct. 16

Cygnus alleges it will suffer $450 mil. in damages and lose $1 bil. in potential revenue over the next 12 years if Sankyo Pharma ceases marketing and distribution of its GlucoWatch non-invasive glucose monitor

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel